Serena Thomas J, Habib Peter, Derosa Amy
General Surgery, Beaumont Health, Livonia, USA.
General Surgery, Beaumont Health, Farmington Hills, USA.
Cureus. 2023 Apr 24;15(4):e38056. doi: 10.7759/cureus.38056. eCollection 2023 Apr.
Background Breast implant illness (BII) is a clinical disease defined by a constellation of symptoms that patients experience as a result of their breast implants. This retrospective, cohort study evaluated the benefit of breast implant explantation with total capsulectomy on patients' symptoms. Methodology This is a single-center, single-arm, cohort study utilizing retrospectively collected data. All participants included in this study voluntarily presented to the department of plastic and reconstructive surgery and requested breast implant removal. A total of 229 patients were enrolled in the study over a three-year period from 2018 to 2021. The primary endpoints of the study were to objectively grade the improvement of symptomatology following surgical intervention. The secondary endpoints were to identify co-factors such as age, comorbidities, implant characteristics, the timing of symptoms, and other data that were potentially influenced by or influencers of the breast implant illness. Results The study achieved a total of 549-point decrease in symptom frequencies following surgery. Furthermore, with an average preoperative symptom score of 3.5 (scored 1-5) and a postoperative average of 1.9, the study demonstrated a score reduction of 1.6 across all symptoms. Furthermore, the study was able to eliminate on average 2.8 symptoms of breast implant illness from every patient following explantation. Conclusion Breast implant illness is a true clinical entity that affects an extensive population of patients who have undergone breast augmentation. This study has not only highlighted the extensive morbidity of breast implant illness but has also demonstrated that there is an opportunity to standardize treatment for this disease. These outcomes have proven that a significant reduction in disease severity can be achieved with breast implant explantation and total capsulectomy.
乳房植入物疾病（BII）是一种临床疾病，由患者因乳房植入物而经历的一系列症状所定义。这项回顾性队列研究评估了乳房植入物取出术联合完全包膜切除术对患者症状的益处。
这是一项单中心、单臂队列研究，利用回顾性收集的数据。本研究纳入的所有参与者均自愿前往整形与重建外科部门并要求取出乳房植入物。在2018年至2021年的三年期间，共有229名患者纳入该研究。该研究的主要终点是客观评估手术干预后症状学的改善情况。次要终点是确定共同因素，如年龄、合并症、植入物特征、症状出现时间以及其他可能受乳房植入物疾病影响或影响乳房植入物疾病的因素。
该研究在手术后症状频率总共降低了549分。此外，术前平均症状评分为3.5（评分范围为1至5），术后平均评分为1.9，该研究表明所有症状的评分降低了1.6。此外，该研究能够在取出植入物后平均消除每位患者2.8种乳房植入物疾病症状。
乳房植入物疾病是一种真正的临床实体，影响着大量接受隆胸手术的患者。这项研究不仅突出了乳房植入物疾病的广泛发病率，还表明有机会对这种疾病的治疗进行标准化。这些结果证明，通过乳房植入物取出术和完全包膜切除术可以显著降低疾病严重程度。
